Liquidia Corp
NASDAQ:LQDA
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.31
16.73
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one LQDA stock under the Base Case scenario is 5.9 USD. Compared to the current market price of 10.51 USD, Liquidia Corp is Overvalued by 44%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Liquidia Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for LQDA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Liquidia Corp
Balance Sheet Decomposition
Liquidia Corp
Current Assets | 147.3m |
Cash & Short-Term Investments | 133.1m |
Receivables | 3.2m |
Other Current Assets | 10.9m |
Non-Current Assets | 30.1m |
PP&E | 7.9m |
Intangibles | 7.2m |
Other Non-Current Assets | 15m |
Current Liabilities | 24.2m |
Accounts Payable | 5.7m |
Accrued Liabilities | 14.3m |
Other Current Liabilities | 4.2m |
Non-Current Liabilities | 90.4m |
Long-Term Debt | 81.8m |
Other Non-Current Liabilities | 8.7m |
Earnings Waterfall
Liquidia Corp
Revenue
|
14.8m
USD
|
Cost of Revenue
|
-4.5m
USD
|
Gross Profit
|
10.3m
USD
|
Operating Expenses
|
-107.6m
USD
|
Operating Income
|
-97.3m
USD
|
Other Expenses
|
-14.8m
USD
|
Net Income
|
-112.1m
USD
|
Free Cash Flow Analysis
Liquidia Corp
USD | |
Free Cash Flow | USD |
LQDA Profitability Score
Profitability Due Diligence
Liquidia Corp's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Liquidia Corp's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
LQDA Solvency Score
Solvency Due Diligence
Liquidia Corp's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Liquidia Corp's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LQDA Price Targets Summary
Liquidia Corp
According to Wall Street analysts, the average 1-year price target for LQDA is 25.84 USD with a low forecast of 17.17 USD and a high forecast of 31.5 USD.
Dividends
Current shareholder yield for LQDA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
Contact
IPO
Employees
Officers
The intrinsic value of one LQDA stock under the Base Case scenario is 5.9 USD.
Compared to the current market price of 10.51 USD, Liquidia Corp is Overvalued by 44%.